Table 5.
Comparison of treatments and outcomes based on histologic subtypes
| Characteristics | DLBCL No. (%) |
MALT No. (%) |
BL No. (%) |
MCL No. (%) |
FL No. (%) |
PTCL-U No. (%) |
EATL No. (%) |
ENKTL No. (%) |
|---|---|---|---|---|---|---|---|---|
| Treatment* | ||||||||
| Chemotherapy | 368 (95.3) | 30 (49.2) | 29 (93.5) | 19 (100.0) | 5 (71.4) | 30 (88.2) | 23 (92.0) | 17 (94.4) |
| Surgical resection | 223 (57.8) | 25 (41.0) | 9 (29.0) | 1 (5.3) | 3 (42.9) | 9 (26.5) | 12 (48.0) | 7 (38.9) |
| Radiotherapy | 32 (8.3) | 13 (21.3) | 2 (6.5) | 1 (5.3) | 2 (28.6) | 4 (11.8) | 1 (4.0) | 1 (5.6) |
| Response | ||||||||
| Complete response | 264 (68.4) | 36 (59.0) | 22 (71.0) | 11 (57.9) | 4 (57.1) | 11 (32.4) | 7 (28.0) | 5 (27.8) |
| Partial response | 36 (9.3) | 5 (8.2) | 5 (16.1) | 5 (26.3) | 0 (0.0) | 4 (11.8) | 4 (16.0) | 3 (16.7) |
| Outcome | ||||||||
| Relapse or Progression | 112 (29.0) | 14 (23.0) | 11 (35.5) | 8 (42.1) | 4 (57.1) | 19 (55.9) | 18 (72.0) | 13 (73.2) |
| Dead | 87 (22.5) | 8 (13.1) | 7 (22.6) | 6 (31.6) | 2 (28.6) | 18 (52.9) | 15 (60.0) | 9 (50.0) |
| Survival | ||||||||
| Median OS | Not reached | Not reached | Not reached | 46 months | 54 months | 35 months | 8.6 months | 7 months |
| 5-year OS | 72% | 88% | 76% | 39% | 42% | 23% | 35% | 45% |
| Median PFS | Not reached | 115 months | Not reached | 31 months | 16 months | 10 months | 4.2 months | 4 months |
| 5-year PFS | 58% | 80% | 60% | 0% | 22% | 17% | 23% | 21% |
*Some patients were treated with combined modality such as surgery plus chemotherapy. Thus, the sum of number of each treatment is larger than total number of patients.
DLBCL: diffuse large B-cell lymphoma; MALT: extranodal marginal zone B-cell lymphoma; BL: Burkitt lymphoma; PTCL-U: peripheral T-cell lymphoma, unspecified; EATL: enteropathy-associated T-cell lymphoma; MCL: mantle cell lymphoma; ENKTL: extranodal natural killer/T-cell lymphoma; FL: follicular lymphoma